Drug Trial Radar · NCT02465515
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,463
Actual
Start
Jul 1, 2015
Primary completion
Feb 20, 2018
Study completion Mar 14, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Duke Clinical Research Institute
- First posted
- Jun 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Conditions
- Diabetes Mellitus
Interventions
Albiglutide 30 mgBiological
Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
Albiglutide 50 mgBiological
Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
Albiglutide matching placeboBiological
Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time PeriodTime frame: Median of 1.65 person years for CV follow-up time period
Locations
607 sites in 28 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Goodyear, Arizona
GSK Investigational Site
Tempe, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Searcy, Arkansas
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
Lancaster, California
GSK Investigational Site
Lomita, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Moreno Valley, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Marino, California
GSK Investigational Site
San Ramon, California
GSK Investigational Site
Simi Valley, California
GSK Investigational Site
Stanford, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Belle Glade, Florida
GSK Investigational Site
Bradenton, Florida
GSK Investigational Site
Bradenton, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Coral Springs, Florida
GSK Investigational Site
Fleming Island, Florida
GSK Investigational Site
Inverness, Florida
GSK Investigational Site
Jacksonville, Florida
Showing 40 of 607 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.